,Article,Date,Symbol,Time,Title,Url
0,"   By Vrinda Manocha  Shares of Alexion Pharmaceuticals Inc (ALXN.O) soared 27 percent to a life-high after the company forecast $2 billion in sales for its blood disorder drug this year ahead of analysts' average estimate.The company, which is also expected to benefit from a lower tax rate, reported sales of $1.55 billion for the drug, Soliris, in 2013.Analysts on average were expecting sales of $1.96 billion for the company's sole drug this year.Alexion said on Thursday it expected its adjusted tax rate to come down to 10-11 percent in 2014. The company is centralizing its global supply chain operations in Ireland and buying a vialing facility there.""Now, essentially, their operations are mostly in Ireland, which makes it more tax-efficient. They don't have to pay U.S. taxes, so that lowers their taxes from about 32 percent,"" Janney Capital analyst Kimberly Lee said. Morningstar analyst Stefan Quenneville said the shift would ""have a significant effect on their bottom line.""Alexion forecast 2014 adjusted earnings of $3.70 to $3.80 per share, higher than analysts' average estimate of $3.46.Sales from Soliris rose about 38 percent to $441.9 million in the fourth quarter ended December 31. Analysts on average had expected sales of $430.7 million, according to Thomson Reuters I/B/E/S.Alexion is able to command a hefty price for Soliris as the drug is the only approved treatment for two rare, life-threatening blood disorders.The drug is also being developed for other ""orphan"" indications, or conditions that affect less than 200,000 people in the United States. Such a status allows the company that is first to market seven years of exclusivity. Net loss for the fourth quarter was $19 million, or 10 cents per share, including a $95.8 million non-cash tax expense and a $33.5 million expense related to impairment of intangible assets.Excluding items, the company earned 87 cents per share, beating the analysts' average estimate of 83 cents per share.Shares of the company were up 22 percent at $163.35 in afternoon trading on the Nasdaq. The stock hit a life-high of $169.98 earlier.More than 4.7 million shares changed hands, nearly 4 times their 10-day moving average.(Reporting by Vrinda Manocha in Bangalore; Editing by Savio D'Souza and Sriraj Kalluvila)",2014-01-30,ALXN,"Thu Jan 30, 2014 | 2:56pm EST","Alexion Pharma sees $2 billion sales, lower tax rate in 2014",http://www.reuters.com//article/us-alexion-results-idUSBREA0T1QB20140130?type=companyNews
1,"  (Adds details from conference call, analysts' comments; updates share movement)By Vrinda ManochaJan 30 Shares of Alexion Pharmaceuticals Inc  soared 27 percent to a life-high after the company forecast $2 billion in sales for its blood disorder drug this year ahead of analysts' average estimate.The company, which is also expected to benefit from a lower tax rate, reported sales of $1.55 billion for the drug, Soliris, in 2013.Analysts on average were expecting sales of $1.96 billion for the company's sole drug this year.Alexion said on Thursday it expected its adjusted tax rate to come down to 10-11 percent in 2014. The company is centralizing its global supply chain operations in Ireland and buying a vialing facility there. ""Now, essentially, their operations are mostly in Ireland, which makes it more tax-efficient. They don't have to pay U.S. taxes, so that lowers their taxes from about 32 percent,"" Janney Capital analyst Kimberly Lee said.Morningstar analyst Stefan Quenneville said the shift would ""have a significant effect on their bottom line.""Alexion forecast 2014 adjusted earnings of $3.70 to $3.80 per share, higher than analysts' average estimate of $3.46. Sales from Soliris rose about 38 percent to $441.9 million in the fourth quarter ended Dec. 31.Analysts on average had expected sales of $430.7 million, according to Thomson Reuters I/B/E/S.Alexion is able to command a hefty price for Soliris as the drug is the only approved treatment for two rare, life-threatening blood disorders. The drug is also being developed for other ""orphan"" indications, or conditions that affect less than 200,000 people in the United States. Such a status allows the company that is first to market seven years of exclusivity.Net loss for the fourth quarter was $19 million, or 10 cents per share, including a $95.8 million non-cash tax expense and a $33.5 million expense related to impairment of intangible assets.Excluding items, the company earned 87 cents per share, beating the analysts' average estimate of 83 cents per share.Shares of the company were up 22 percent at $163.35 in afternoon trading on the Nasdaq. The stock hit a life-high of $169.98 earlier.More than 4.7 million shares changed hands, nearly 4 times their 10-day moving average.   (Reporting by Vrinda Manocha in Bangalore; Editing by Savio D'Souza and Sriraj Kalluvila)",2014-01-30,ALXN,"Thu Jan 30, 2014 | 2:56pm EST","UPDATE 1-Alexion Pharma sees $2 bln sales, lower tax rate in 2014",http://www.reuters.com//article/alexion-results-idUSL3N0L452G20140130?type=companyNews
2,"  Jan 30 Alexion Pharmaceuticals Inc said it expected revenue from its blood disorder drug, Soliris, to hit the $2 billion mark in 2014, sending its shares up 27 percent to a life-high.The company reported fourth-quarter results and forecast full-year results ahead of analysts' expectations, helped by soaring sales of the drug.Soliris is the company's sole drug. It is the only approved treatment for two rare, life-threating blood disorders, allowing Alexion to command a hefty price.The drug is also being developed for other orphan indications, or condition affecting less than 200,000 people. Sales from Soliris rose about 38 percent to $441.9 million in the fourth quarter ended Dec. 31. Sales are expected to rise to between $2 billion to $2.02 billion in 2014 from $1.55 billion in 2013.Analysts on average were expecting sales of $430.7 million in the fourth quarter and sales of $1.96 billion in 2014, according to Thomson Reuters I/B/E/S. Alexion forecast 2014 adjusted earnings of $3.70 to $3.80 per share, higher than analysts' estimate of $3.46.Net loss for the fourth quarter was $19 million, or 10 cents per share, including a $95.8 million non-cash tax expense and a $33.5 million expense related to the impairment of intangible assets. The company earned $81 million, or 40 cents per share, a year earlier.Excluding items, the company earned 87 cents per share in the latest quarter, beating the analysts' average estimate of 83 cents per share.Shares of the company were trading up 23 percent at $164.34 in morning trading on Thursday on the Nasdaq. The stock hit a life-high of $169.98 earlier.   (Reporting by Vrinda Manocha in Bangalore; Editing by Savio D'Souza)",2014-01-30,ALXN,"Thu Jan 30, 2014 | 10:14am EST",Alexion Pharma sees Soliris sales topping $2 bln in 2014,http://www.reuters.com//article/alexion-results-idUSL3N0L44ST20140130?type=companyNews
3,"  LONDON, March 4 Britain's healthcare costs watchdog has asked U.S. biotech group Alexion Pharmaceuticals  to explain the high price for its Soliris drug before deciding whether the treatment should be paid for by the state health service.Funding Soliris for the around 200 patients in England it could benefit would cost an estimated 58 million pounds ($97 million) in the first year, rising to 80 million pounds a year in five years time, the National Institute for Health and Care Excellence (NICE) said.Soliris is designed to treat two extremely rare chronic genetic conditions that can damage vital organs including the kidneys, heart and brain and has a U.S. list price of about $440,000 per patient a year.""Drugs for very rare conditions that affect just a few people in the country are inevitably more expensive than for more common diseases,"" said NICE's chief executive Andrew Dillon. ""However, before we can make a confident recommendation for routine use (of Soliris) ... we need more information."" He said that while Soliris is recognised as an effective drug, NICE's independent advisory committee wants more information from Alexion ""on aspects of the manufacturing, research and development costs"" of a rare disease medicine.The committee had also asked the country's taxpayer-funded National Health Service for more general information about the costs of highly specialised treatments, he said. Alexion criticised NICE for further delaying a decision, but said it would continue to work with the costs body.Sales of Soliris are forecast by analysts to reach $3.1 billion a year by 2017. NICE is evaluating the cost effectiveness of Soliris' use in a condition called atypical Haemolytic Uraemic Syndrome (aHUS) that causes severe inflammation of blood vessels and the formation of blood clots in small blood vessels.The drug, given intravenously as initial treatment at a dose of 900 milligrams (mg) for four weeks, and then for maintenance at a higher dose, but with treatments only every 12 to 16 weeks, costs 3,150 pounds per 30 millilitre vial in Britain, giving a treatment cost of 340,200 pounds per adult patient in the first year, according to NICE.The summary product characteristics for the drug also states that ""treatment is recommended to continue for a patient's lifetime, unless discontinuation of treatment is clinically indicated"".",2014-03-04,ALXN,"Mon Mar 3, 2014 | 7:01pm EST",British watchdog wants U.S. biotech Alexion to justify cost of drug,http://www.reuters.com//article/alexion-nice-soliris-idUSL6N0M02RR20140304?type=companyNews
4,"  Alexion Pharmaceuticals Inc (ALXN.O) raised its profit and sales forecast for the year after the French government agreed to raise reimbursement payments for the company's treatment for two rare blood disorders.The company's stock jumped nearly 7 percent in afternoon trade.The drug, Soliris, which costs about $440,000 per patient a year, is the only approved treatment for two potentially fatal conditions that can damage vital organs including the kidneys, heart and brain.Soliris, the company's sole product on the market, is approved in the United States, the European Union and Japan for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.""This is a testament to the drug's dramatic (therapeutic) effect,"" Morningstar analyst Stefan Quenneville said, as Alexion continues to achieve favorable reimbursement terms even in an austere pricing environment in Europe.Deutsche Bank analysts said the French government's decision should bode well for Alexion's ongoing reimbursement discussions in Spain and Italy. Britain's healthcare costs watchdog earlier this month asked the biotechnology company to explain Soliris' expensive price before deciding whether the treatment should be paid for by the state health service.Wall Street expects the drug to generate $3.1 billion a year by 2017. Wells Fargo analyst Brian Abrahams said the company's raised forecast was somewhat unexpected, even though he had assumed that the company's negotiations with the French government would result in a positive outcome.The drugmaker raised its full-year adjusted earnings forecast to $4.37-$4.47 per share from its previous estimate of $3.70-$3.80.The company raised its sales outlook to $2.15-$2.17 billion from $2.00-$2.02 billion. Alexion said the earnings estimate includes 37 cents and $88 million attributable to sales related to years prior to 2014, which would be recorded in the first quarter.Soliris is also undergoing development for use in other ""orphan"" indications, or conditions that affect less than 200,000 people in the United States. The status ensures the company seven years of market exclusivity.Cheshire, Connecticut-based Alexion's shares were trading at $179.51 on the Nasdaq. They have gained over 80 percent of their value over the past year.(Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila)",2014-03-10,ALXN,"Mon Mar 10, 2014 | 2:00pm EDT",Alexion raises forecast as France boosts Soliris reimbursement,http://www.reuters.com//article/us-alexion-outlook-idUSBREA290I120140310?type=companyNews
5,"  * Decision should help reimbursement talks in Spain, Italy-analyst* Shares rise as much as 7 pct   (Adds background, analysts comments; Updates shares)March 10 Alexion Pharmaceuticals Inc  raised its profit and sales forecast for the year after the French government agreed to raise reimbursement payments for the company's treatment for two rare blood disorders.The company's stock jumped nearly 7 percent in afternoon trade.The drug, Soliris, which costs about $440,000 per patient a year, is the only approved treatment for two potentially fatal conditions that can damage vital organs including the kidneys, heart and brain.Soliris, the company's sole product on the market, is approved in the United States, the European Union and Japan for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. ""This is a testament to the drug's dramatic (therapeutic) effect,"" Morningstar analyst Stefan Quenneville said, as Alexion continues to achieve favorable reimbursement terms even in an austere pricing environment in Europe.Deutsche Bank analysts said the French government's decision should bode well for Alexion's ongoing reimbursement discussions in Spain and Italy.Britain's healthcare costs watchdog earlier this month asked the biotechnology company to explain Soliris' expensive price before deciding whether the treatment should be paid for by the state health service. Wall Street expects the drug to generate $3.1 billion a year by 2017.Wells Fargo analyst Brian Abrahams said the company's raised forecast was somewhat unexpected, even though he had assumed that the company's negotiations with the French government would result in a positive outcome. The drugmaker raised its full-year adjusted earnings forecast to $4.37-$4.47 per share from its previous estimate of $3.70-$3.80.The company raised its sales outlook to $2.15-$2.17 billion from $2.00-$2.02 billion.Alexion said the earnings estimate includes 37 cents and $88 million attributable to sales related to years prior to 2014, which would be recorded in the first quarter.Soliris is also undergoing development for use in other ""orphan"" indications, or conditions that affect less than 200,000 people in the United States. The status ensures the company seven years of market exclusivity.Cheshire, Connecticut-based Alexion's shares were trading at $179.51 on the Nasdaq. They have gained over 80 percent of their value over the past year.   (Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila)",2014-03-10,ALXN,"Mon Mar 10, 2014 | 1:59pm EDT",UPDATE 2-Alexion raises forecast as France boosts Soliris reimbursement,http://www.reuters.com//article/alexion-outlook-idUSL3N0M735L20140310?type=companyNews
6,"  March 10 Alexion Pharmaceuticals Inc  revised its profit and sales outlook for the year after the French government agreed to raise reimbursement payments for the company's lead drug, Soliris.The company's shares rose nearly 3 percent before the bell.Alexion said it would record about $88 million of additional sales in the first quarter as reimbursement related to Soliris sales in prior years. The drugmaker raised its full-year adjusted earnings forecast to $4.37-$4.47 per share from its previous estimate of $3.70-$3.80 per share.Alexion also raised its sales outlook to $2.15-$2.17 billion from its previous forecast of $2.00-$2.02 billion. Analysts on average were expecting a profit of $3.89 per share on sales of $2.03 billion, according to Thomson Reuters I/B/E/S. Soliris is the only approved treatment for two rare, life-threatening blood disorders.Chestire, Connecticut based Alexion's stock closed at $168.05 on Friday on the Nasdaq.",2014-03-10,ALXN,"Mon Mar 10, 2014 | 7:08am EDT","Alexion to book additional Soliris sales, raises outlook",http://www.reuters.com//article/alexion-outlook-idUSL3N0M730X20140310?type=companyNews
7,"  * Raises 2014 adj earnings forecast to $4.75-$4.85/share* 1st-quarter adj earnings $1.53/share vs est $1.26   (Adds details, analyst comment)By Natalie GroverApril 24 Alexion Pharmaceuticals Inc  raised its full-year profit forecast for the second time in less than two months after robust sales of its rare-diseases drug Soliris helped it beat average earnings estimate in the first quarter.Sales of Soliris, Alexion's only drug on the market, rose about 67 percent to $566.6 million, including $87.8 million related to reimbursement of prior-year shipments to France.Analysts had expected revenue of $560.2 million, according to Thomson Reuters I/B/E/S. The biotechnology company raised its full-year adjusted earnings forecast to $4.75-$4.85 per share from $4.37-$4.47.The company cut its selling, general and administrative expense estimate for the full year by $10 million to $550-$570 million, and lowered its estimate for adjusted tax rate by 2 percentage points to 8-9 percent. The company first raised its profit and sales forecast in March after the French government agreed to raise reimbursement payments for prior shipments of Soliris.Morningstar analyst Stefan Quenneville said the company was exhibiting a ""relatively good operating leverage"", considering its focus on rare, ""orphan"" indications, or conditions that affect less than 200,000 people in the United States.Soliris, which costs about $440,000 per patient a year, is the only approved treatment for two potentially fatal blood disorders that can damage the kidneys, heart and brain. It is approved in the United States, the European Union and Japan for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Alexion's net income rose to $159.4 million, or 79 cents per share, in the quarter ended March 31, from $82.2 million, or 41 cents per share, a year earlier.Excluding special items, earnings were $1.53 per share, above analysts' average estimate of $1.26.Cheshire, Connecticut-based Alexion's shares were up more than 1 percent at $154.82 in morning trading on the Nasdaq on Thursday.   (Editing by Maju Samuel and Don Sebastian)",2014-04-24,ALXN,"Thu Apr 24, 2014 | 10:23am EDT",UPDATE 1-Alexion Pharma raises 2014 profit forecast again,http://www.reuters.com//article/alexionpharmaceuticals-results-idUSL3N0NG4KL20140424?type=companyNews
8,"  April 24 Alexion Pharmaceuticals Inc  reported stronger-than-expected adjusted net earnings due to robust sales of its sole product on the market, Soliris, and it raised its full-year profit forecast for the second time in less than two months.The drugmaker's shares rose about 5 percent before the bell.The company raised its full-year adjusted earnings per share guidance to $4.75-$4.85 from $4.37-$4.47, which it forecast on March 10.Soliris, which costs about $440,000 per patient a year, is the only approved treatment for two potentially fatal conditions that can damage vital organs including the kidneys, heart and brain. Alexion's net income rose to $159.4 million, or 79 cents per share, in the first quarter ended March 31, from $82.2 million, or 41 cents per share, a year earlier. Excluding special items, earnings were $1.53 per share.Net product sales rose about 67 percent to $566.6 million, which includes the reimbursement of prior-year Soliris shipments related to an $87.8 million agreement with the French government. Analysts had expected earnings of $1.26 per share on revenue of $560.2 million, according to Thomson Reuters I/B/E/S.Cheshire, Connecticut-based Alexion's shares were at $160.02 in premarket trading after closing at $152.23 on the Nasdaq on Wednesday.   (Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)",2014-04-24,ALXN,"Thu Apr 24, 2014 | 8:37am EDT",Alexion Pharma raises 2014 profit forecast on strong Soliris sales,http://www.reuters.com//article/alexionpharmaceuticals-results-idUSL3N0NG49B20140424?type=companyNews
9,"  Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.Alexion initiated the recall due to the presence of visible particles found in a single lot of Soliris during a test, the company said in a statement. The company said it did not expect the recall to have any financial impact or interrupt supply of the drug.   (Reporting by Sruthi Ramakrishnan in Bangalore, Editing by Simon Jennings)",2014-06-02,ALXN,"Mon Jun 2, 2014 | 7:29am EDT",Alexion Pharma recalls certain lots of intravenous drug Soliris,http://www.reuters.com//article/us-alexion-recall-idUSKBN0ED11L20140602?type=companyNews
10,"  June 2 Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November. Alexion initiated the recall due to the presence of visible particles found in a single lot of Soliris during a test, the company said in a statement.  The company said it did not expect the recall to have any financial impact or interrupt supply of the drug.   (Reporting by Sruthi Ramakrishnan in Bangalore, Editing by Simon Jennings)",2014-06-02,ALXN,"Mon Jun 2, 2014 | 7:27am EDT",Alexion Pharma recalls certain lots of intravenous drug Soliris,http://www.reuters.com//article/alexion-recall-idUSL3N0OJ2CL20140602?type=companyNews
11,"  LONDON, Sept 4 Britain's healthcare cost watchdog has recommended a drug to treat a rare blood disease from U.S. biotech group Alexion Pharmaceuticals, even though it said the medicine was ""very expensive"".In March, the National Institute for Health and Care Excellence (NICE) had sought more information from the company explaining the high price of Soliris.The medicine is designed to treat two rare chronic genetic conditions that can damage organs including the kidneys, heart and brain. NICE said it would cost 340,200 pounds ($560,500) per adult patient in the first year and 327,600 pounds thereafter. The draft guidance from NICE, which is now open to consultation, covers use of Soliris in a condition called atypical Haemolytic Uraemic Syndrome (aHUS) that causes severe inflammation of blood vessels. ""From the available evidence and from the testimony of clinicians and patients, families and carers, it is clear that eculizumab is a significant breakthrough in the management of aHUS,"" said NICE's chief executive Andrew Dillon. ""The drug is, however, very expensive."" Funding Soliris - also known as eculizumab - for the around 200 patients in England it could benefit would cost an estimated 58 million pounds in the first year, rising to 82 million pounds a year in five years time, NICE added. ($1 = 0.6069 British Pounds)   (Reporting by Ben Hirschler, editing by Louise Heavens)",2014-09-03,ALXN,"Wed Sep 3, 2014 | 7:01pm EDT","UK watchdog backs Alexion's ""very expensive"" drug",http://www.reuters.com//article/alexion-pharm-britain-idUSL5N0R41J320140903?type=companyNews
12,"  (Adds details, background)Oct 23 Alexion Pharmaceuticals Inc  reported a better-than-expected adjusted quarterly profit on strong sales of its blood disorder drug Soliris and raised its full-year profit forecast for the fourth time this year.Sales of Soliris, Alexion's only drug on the market, rose 39 percent to $555.1 million from a year earlier, beating the average analyst estimate of $541.9 million, according to Thomson Reuters I/B/E/S.Soliris is the only approved treatment for two potentially fatal blood disorders that can damage the kidneys, heart and brain. It is approved in the United States, the European Union and Japan for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome (aHUS).The biotechnology company raised its full-year 2014 adjusted earnings forecast to $5.15 to $5.20 per share, from $4.95 to $5.05 per share. It also raised its revenue forecast to a range of $2.22 billion to $2.23 billion, from its prior view of $2.18 to $2.20 billion.Analysts expected the company to post a full-year profit of $5.01 per share on revenue of $2.20 billion. Alexion's net income rose to $177.7 million, or 88 cents per share, in the third quarter ended Sept. 30, from $93.8 million, or 47 cents per share, a year earlier.Excluding special items, it earned $1.27 per share, beating the average analyst estimate of $1.16 per share, according to Thomson Reuters I/B/E/S.Alexion shares were up about 3.6 percent at $179.50 in premarket trading on the Nasdaq on Thursday. Up to Thursday's close, the stock had risen more than 30 percent this year.   (Reporting by Shailesh Kuber in Bangalore; Editing by Simon Jennings)",2014-10-23,ALXN,"Thu Oct 23, 2014 | 8:55am EDT","UPDATE 1-Alexion Pharma quarterly adj profit beats, raises forecast again",http://www.reuters.com//article/alexion-results-idUSL3N0SI4HW20141023?type=companyNews
13,"  Oct 23 Alexion Pharmaceuticals Inc  reported a better-than-expected adjusted profit on strong sales of its blood disorder drug Soliris and raised its full-year profit forecast for the fourth time this year.Sales of Soliris, Alexion's only drug on the market, rose 39 percent to $555.1 million from a year earlier. The company raised its full-year 2014 adjusted earnings per share forecast to $5.15 to $5.20 per share from $4.95 to $5.05 per share. Excluding special items, Alexion posted earnings of $1.27 per share in the third quarter ended Sept. 30, beating the average analyst estimate of $1.16 per share, according to Thomson Reuters I/B/E/S. Alexion shares were up 2 percent in premarket trading on Thursday. The stock closed at $173.27 on the Nasdaq on Wednesday.   (Reporting by Shailesh Kuber; Editing by Simon Jennings)",2014-10-23,ALXN,"Thu Oct 23, 2014 | 7:18am EDT","Alexion Pharma quarterly adj profit beats, raises forecast again",http://www.reuters.com//article/alexion-results-idUSL3N0SI4AS20141023?type=companyNews
14,"   By Vidya L Nathan, Natalie Grover and Bill Berkrot  Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases.Alexion's willingness to pay an eye-popping premium for Synageva demonstrates that the appetite for large acquisitions in healthcare continues unabated. It also highlights the attraction of medicines for rare diseases that can command exceptionally high prices with little payer pushback because of  the limited number of patients.Alexion's lone product, Soliris, a treatment for two extremely rare life-threatening conditions, is among the world's most expensive drugs. The medicine, which can cost more than $500,000 per year, generated sales of $2.23 billion in 2014.The companies' combined developmental pipelines would give Alexion eight experimental medicines in clinical trials for 11 diseases, the company said. That includes Synageva's Kanuma, which is awaiting U.S. and European approval to treat a rare and potentially fatal condition that causes a build-up of fat in the blood and liver.Alexion Chief Executive David Hallal expressed confidence that Kanuma sales will eventually exceed $1 billion.The deal would also give Alexion Synageva's SBC-103, an experimental enzyme replacement therapy for a rare genetic disorder that has both orphan status and fast-track designation from the U.S. Food and Drug Administration. That should speed up the approval process and, in the event of approval, confer an additional seven years of marketing exclusivity, an incentive for developing medicines for small patient populations.""I think Alexion wanted to do something big. There aren't many opportunities ... to do that, and so this is their big shot,"" said Paul Yook, portfolio manager at BioShares Biotechnology Funds, which holds stakes in both companies. Yook said the announcement could put Alexion in the takeover crosshairs. ""Anybody who's been looking at them now will have to make a move more quickly if they don't want to acquire Synageva as well.""MORE RAISED EYEBROWS Alexion is offering $115 in cash and 0.6581 of its shares, or $225.92 per Synageva share, more than double its closing price of $95.87 on Tuesday.  ""While some investors may be picking their jaws off the floor at such a valuation, we note that Synageva has only disclosed a fraction of its development efforts,"" Baird Equity Research analyst Christopher Raymond said.Synageva's shares soared on Wednesday, ending regular trading at $203.39, up 112 percent. Alexion shares traded as low as $150.06 before finishing at $155.01, down 8 percent, a sign of investor dissatisfaction with the price the company agreed to pay for Synageva.Paul Hudson, president of AstraZeneca's U.S. operations, speaking at the FT US Healthcare and Life Sciences Conference in New York, said he expects to see ""more raised eyebrows"" over future deal valuations. Whether you end up paying a high valuation is based on ""whether you see some magic that others donâ€™t see,"" he said. The deal would provide a windfall for Baker Brothers Investments, which owns about 32 percent of Synageva and stands to make $2.68 billion.There has been a steady wave of recent deals and takeover efforts in healthcare, including AbbVie's nearly $21 billion deal for Pharmacyclics and Pfizer's planned $16.7 billion purchase of Hospira. In the rare-disease space, Teva Pharmaceutical Industries  bought Auspex Pharmaceuticals for $3.5 billion, and Shire acquired NPS Pharmaceuticals for $5.2 billion. Meanwhile, Teva is pursuing generic drugmaker rival Mylan, which rejected a $43 billion offer and is itself trying to buy Ireland-based Perrigo, which in turn rebuffed Mylan's $34 billion bid. Lazard and JPMorgan were Alexion's financial advisers, while Goldman Sachs advised Synageva.Wachtell Lipton Rosen & Katz is Alexion's legal counsel, while Sullivan & Cromwell LLP and Ropes & Gray LLP are Synageva's legal counsel. (Additional reporting by Caroline Humer in New York and Ankur Banerjee in Bangaluru; Editing by Savio D'Souza, Saumyadeb Chakrabarty and Steve Orlofsky)",2015-05-06,ALXN,"Wed May 6, 2015 | 5:49pm EDT",Alexion to bolster rare disease offering with $8.4 billion deal,http://www.reuters.com//article/us-synageva-m-a-alexion-idUSKBN0NR14120150506?type=companyNews
15,"   By Olivia Oran  The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.Alexion shares fell as much as 10 percent on Wednesday on investor concerns the $8.4 billion cash and stock deal overvalued Synageva, whose drug for a rare and potentially fatal condition that causes a build-up of fat in the blood and liver awaits regulatory approval.Alexion offered Synageva nearly a 140 percent premium, versus an average takeover premium of 41 percent for biotechnology companies so far this year, according to Thomson Reuters data. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5 billion purchase of Auspex Pharmaceuticals announced in March and Shire Plc's acquisition of NPS Pharmaceuticals for $5.2 billion in January.Reuters also reported last week that Pfizer Inc had made a preliminary offer for rare-disease drug maker Swedish Orphan Biovitrium AB. Orphan drug companies are seen as attractive because they can typically charge higher prices for their drugs, which serve small patient populations. The U.S. Food and Drug Administration's approval process for these drugs is also often quicker - around 10 months versus at least 1 year for non-orphan drugs. This is because these drugs treat serious or life threatening diseases when other treatment options may not exist. ""Rare-disease companies are profitable businesses and the cost to market a product is pretty low, which makes them attractive targets,"" said Lisa Bayko, an analyst with JMP Securities. ""The drugs seem to sell themselves to some degree."" In turn, major drug companies such as Pfizer, Celgene Corp and Novartis AG are investing heavily in orphan drugs. While rare diseases were historically ignored by large pharmaceutical companies in favor of those with larger patient populations such as cardiac disease and diabetes, orphan made up almost half of the 41 new drugs approved by the FDA last year.  Sales of orphan drugs are expected to grow at an annual rate of almost 11 percent per year through 2020, compared with 4 percent for drugs treating larger populations, according to a recent report from research firm EvaluatePharma. However, some experts argue that orphan drug companies do not necessarily make for the best investments, because they are overvalued by the market and may carry R&D risk. ""When you have large pharmaceutical companies that aren't already in the orphan sector paying large premiums, it enters into really risky territory,"" said Steve Brozak, president of WBB Securities LLC. ""It's going to be problematic for companies and investors that don't understand all the processes of manufacturing, development and patient advocacy.""  U.S. pharmaceutical merger activity has topped $107.3 billion so far this year, more than double the volume a year ago. (This story has been corrected to fix spelling of analyst's name to Liisa Bayko from Lisa Bayko in seventh paragraph)  (Reporting by Olivia Oran in New York; Editing by Greg Roumeliotis and Steve Orlofsky)",2015-05-06,ALXN,"Wed May 6, 2015 | 5:49pm EDT",Rich Synageva M&A premium epitomizes appetite for orphan drugs,http://www.reuters.com//article/us-raredisease-m-a-idUSKBN0NR2B620150506?type=companyNews
16,"  (In paragraph 7 corrects spelling of analyst's name to Liisa Bayko from Lisa Bayko)By Olivia OranMay 6 The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.Alexion shares fell as much as 10 percent on Wednesday on investor concerns the $8.4 billion cash and stock deal overvalued Synageva, whose drug for a rare and potentially fatal condition that causes a build-up of fat in the blood and liver awaits regulatory approval.Alexion offered Synageva nearly a 140 percent premium, versus an average takeover premium of 41 percent for biotechnology companies so far this year, according to Thomson Reuters data.Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5 billion purchase of Auspex Pharmaceuticals announced in March and Shire Plc's acquisition of NPS Pharmaceuticals for $5.2 billion in January. Reuters also reported last week that Pfizer Inc had made a preliminary offer for rare-disease drug maker Swedish Orphan Biovitrium AB. Orphan drug companies are seen as attractive because they can typically charge higher prices for their drugs, which serve small patient populations. The U.S. Food and Drug Administration's approval process for these drugs is also often quicker - around 10 months versus at least 1 year for non-orphan drugs. This is because these drugs treat serious or life threatening diseases when other treatment options may not exist.""Rare-disease companies are profitable businesses and the cost to market a product is pretty low, which makes them attractive targets,"" said Liisa Bayko, an analyst with JMP Securities. ""The drugs seem to sell themselves to some degree."" In turn, major drug companies such as Pfizer, Celgene Corp  and Novartis AG are investing heavily in orphan drugs. While rare diseases were historically ignored by large pharmaceutical companies in favor of those with larger patient populations such as cardiac disease and diabetes, orphan made up almost half of the 41 new drugs approved by the FDA last year.Sales of orphan drugs are expected to grow at an annual rate of almost 11 percent per year through 2020, compared with 4 percent for drugs treating larger populations, according to a recent report from research firm EvaluatePharma.However, some experts argue that orphan drug companies do not necessarily make for the best investments, because they are overvalued by the market and may carry R&D risk.""When you have large pharmaceutical companies that aren't already in the orphan sector paying large premiums, it enters into really risky territory,"" said Steve Brozak, president of WBB Securities LLC. ""It's going to be problematic for companies and investors that don't understand all the processes of manufacturing, development and patient advocacy.""U.S. pharmaceutical merger activity has topped $107.3 billion so far this year, more than double the volume a year ago.    (Reporting by Olivia Oran in New York; Editing by Greg Roumeliotis and Steve Orlofsky)",2015-05-06,ALXN,"Wed May 6, 2015 | 4:41pm EDT",CORRECTED-Rich Synageva M&A premium epitomizes appetite for orphan drugs,http://www.reuters.com//article/raredisease-ma-idUSL1N0XX1FB20150506?type=companyNews
17,"  (Adds Western Union, BNP Paribas, Canadian Tire, Centrais Eletricas Brasileiras SA)May 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease. The deal is expected to add to Alexion's 2018 profit, while allowing $150 million in cost savings in 2017, the companies said in a statement on Wednesday.** German chemicals maker Evonik Industries AG, which last year raised expectations of a larger takeover deal, said it would not pursue a transaction for its own sake and might return money to shareholders if no suitable target is found.** Western Union Co, the world's largest money transfer company, said on Wednesday that it is not in talks to buy smaller rival MoneyGram International Inc.** French bank BNP Paribas said it was selling part of its stake in French shopping mall operator Klepierre  through a private placement with institutional investors.** Retailer Canadian Tire Corp Ltd said it would buy leases for 12 properties previously held by the Canadian unit of Target Corp for $17.7 million.** Centrais Eletricas Brasileiras SA, Brazil's largest power holding company, is considering selling controlling stakes in several power distribution companies to focus on generation and transmission of electricity, a source with direct knowledge of the situation said.** Airbus Group NV aims to strike a new sales deal for its A400M military aircraft this year and hopes it will bolster interest in the delay-plagued transporter, a senior executive from its defense division said. Several buyers, including Turkey and Germany, have expressed frustration at repeated delays in deliveries of the heavy cargo and troop carrier, Europe's largest defense project. ** Japan's plan to buy V-22 tilt-rotor aircraft built by Boeing Co and Textron Inc's Bell Helicopter unit moved forward this week with a formal notification to the U.S. Congress about the $3 billion deal.** Crestwood Equity Partners LP said it would buy affiliate Crestwood Midstream Partners LP in a $3.5 billion stock deal to simplify its corporate structure.** Newly formed mining and metals group South32 is open to acquisitions once it splits from BHP Billiton , CEO-elect Graham Kerr said on Wednesday. BHP shareholders in Australia and Britain voting by proxy overwhelmingly approved the spin-off, which includes some of the global miner's smaller assets, at meetings in Perth and London on Wednesday, paving the way for a listing on May 18.** Mikhail Fridman's LetterOne fund is set to formally launch sale of North Sea gas fields it had acquired from RWE , bowing to British threats to revoke the assets' license unless the Russian tycoon relinquishes ownership. ** Japanese's Daiwa Securities Group Inc is keen to buy a minority stake in Malaysia's Affin Hwang Investment Bank Bhd, parent Affin Holdings Bhd said on Wednesday. Affin, Malaysia's smallest lender by market value, said on Wednesday the central bank had no objection in principle to it starting negotiations with Daiwa Securities.** German roof-tile maker Braas-Monier is on the lookout for further acquisitions after recent buys in southern Europe and Asia, its chief executive told Reuters on Wednesday.** Brokerage BGC Partners Inc said on Tuesday it had agreed to buy real estate consulting firm Computerized Facility Integration LLC for an undisclosed sum, in an acquisition that highlights the growing need for companies to wring costs and boost efficiencies from a global network of corporate properties and facilities.** ZF Friedrichshafen AG and TRW Automotive Holdings Corp have won U.S. antitrust approval for their merger on condition that they sell assets, the Federal Trade Commission said on Tuesday. ** Mexican oil and gas company Alfa Sab de CV and Harbour Energy Ltd have agreed to acquire Canadian peer Pacific Rubiales Energy Corp for C$6 billion ($4.99 billion), including debt, a person familiar with the matter said on Tuesday.** A long-expected consolidation of Brazil's telecoms industry that is likely to involve rivals Oi and TIM  has run into delays but should go ahead in 2016, a representative of Oi's largest shareholder, Portugal Telecom SGPS, said on Tuesday.** Generic drug maker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it was fully committed to acquiring Ireland-based Perrigo Co  and that it believed it could complete the deal by year end. Mylan, on a conference call with analysts, said it was legally committed to take its offer directly to Perrigo shareholders under Irish takeover rules. As proposed, the deal would give current Perrigo shareholders 39 percent of the combined company.** TPG Telecom Ltd, an Australian internet provider controlled by Malaysian-born billionaire David Teoh, has sweetened its approach for rival iiNet Ltd to at least A$1.56 billion ($1.24 billion), battling an offer from rival M2 Group Ltd.** Kinross Gold is scouting for acquisition opportunities but vows it will be disciplined and only strike a deal if it offers value to shareholders, the Canadian gold miner's chief executive said on Tuesday.** Tune Ins Holdings Bhd, 13.65 percent-owned by Malaysian budget carrier AirAsia, said it would buy half of unlisted Indonesian insurance provider PT Asuransi Staco Mandiri for 82.9 billion rupiah ($6.4 million).** Apple Inc's move to line up deals with record labels is under U.S. antitrust scrutiny as the iPhone maker prepares to debut a new version of the Beats Music streaming service, Bloomberg reported, citing people familiar with the matter.($1 = 13,030 Indonesian rupiah)  ($1 = C$1.20)  ($1 = 1.2607 Australian dollars)   (Compiled by Rosmi Shaji and Neha Dimri in Bengaluru)",2015-05-06,ALXN,"Wed May 6, 2015 | 4:02pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0XX3T220150506?type=companyNews
18,"  * Alexion offers $225.92 per Synageva share in cash and stock* Offer represents premium of 135.7 pct to Synageva's close* Deal gives Alexion access to potential blockbuster Kanuma* Alexion shares down 10 pct; Synageva shares trading above $204   (Adds investor, AstraZeneca executive comment, background, updates shares)By Vidya L Nathan, Natalie Grover and Bill BerkrotMay 6 Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp  for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases.Alexion's willingness to pay an eye-popping premium for Synageva demonstrates that the appetite for large acquisitions in healthcare continues unabated. It also highlights the attraction of medicines for rare diseases that can command exceptionally high prices with little payer pushback because of  the limited number of patients.Alexion's lone product, Soliris, a treatment for two extremely rare life-threatening conditions, is among the world's most expensive drugs. The medicine, which can cost more than $500,000 per year, generated sales of $2.23 billion in 2014.The companies' combined developmental pipelines would give Alexion eight experimental medicines in clinical trials for 11 diseases, the company said. That includes Synageva's Kanuma, which is awaiting U.S. and European approval to treat a rare and potentially fatal condition that causes a build-up of fat in the blood and liver. Alexion Chief Executive David Hallal expressed confidence that Kanuma sales will eventually exceed $1 billion.The deal would also give Alexion Synageva's SBC-103, an experimental enzyme replacement therapy for a rare genetic disorder that has both orphan status and fast-track designation from the U.S. Food and Drug Administration. That should speed up the approval process and, in the event of approval, confer an additional seven years of marketing exclusivity, an incentive for developing medicines for small patient populations.""I think Alexion wanted to do something big. There aren't many opportunities ... to do that, and so this is their big shot,"" said Paul Yook, portfolio manager at BioShares Biotechnology Funds, which holds stakes in both companies.Yook said the announcement could put Alexion in the takeover crosshairs. ""Anybody who's been looking at them now will have to make a move more quickly if they don't want to acquire Synageva as well."" MORE RAISED EYEBROWS Alexion is offering $115 in cash and 0.6581 of its shares, or $225.92 per Synageva share, more than double its closing price of $95.87 on Tuesday.""While some investors may be picking their jaws off the floor at such a valuation, we note that Synageva has only disclosed a fraction of its development efforts,"" Baird Equity Research analyst Christopher Raymond said. Synageva's shares soared on Wednesday, trading at $204.36. Alexion shares were off more than 10 percent at $151.65, signaling investor dissatisfaction with the price the company agreed to pay for Synageva.Paul Hudson, president of AstraZeneca's U.S. operations, speaking at the FT US Healthcare and Life Sciences Conference in New York, said he expects to see ""more raised eyebrows"" over future deal valuations. Whether you end up paying a high valuation is based on ""whether you see some magic that others don't see,"" he said.The deal would provide a windfall for Baker Brothers Investments, which owns about 32 percent of Synageva and stands to make $2.68 billion.There has been a steady wave of recent deals and takeover efforts in healthcare, including AbbVie's nearly $21 billion deal for Pharmacyclics and Pfizer's  planned $16.7 billion purchase of Hospira.In the rare-disease space, Teva Pharmaceutical Industries   bought Auspex Pharmaceuticals for $3.5 billion, and Shire acquired NPS Pharmaceuticals for $5.2 billion. Meanwhile, Teva is pursuing generic drugmaker rival Mylan , which rejected a $43 billion offer and is itself trying to buy Ireland-based Perrigo, which in turn rebuffed Mylan's $34 billion bid.Lazard and JPMorgan were Alexion's financial advisers, while Goldman Sachs advised Synageva.Wachtell Lipton Rosen & Katz is Alexion's legal counsel, while Sullivan & Cromwell LLP and Ropes & Gray LLP are Synageva's legal counsel.   (Additional reporting by Caroline Humer in New York and Ankur Banerjee in Bangaluru; Editing by Savio D'Souza, Saumyadeb Chakrabarty and Steve Orlofsky)",2015-05-06,ALXN,"Wed May 6, 2015 | 2:31pm EDT",UPDATE 4-Alexion to bolster rare disease offering with $8.4 bln deal,http://www.reuters.com//article/synageva-ma-alexion-idUSL4N0XX3BW20150506?type=companyNews
19,"  LONDON, June 26 New drugs from Novartis  and Alexion won a green light from European regulators on Friday, delivering a boost to both drugmakers and offering new treatment options for cancer and rare diseases.Experts from the European Medicines Agency (EMA) said they had recommended approval of Novartis's Farydak for multiple myeloma, an aggressive blood cancer, and Odomzo for basal cell carcinoma, a type of skin cancer.Farydak won U.S. approval in February. Alexion, which specialises in high-priced drugs for niche diseases, won a recommendation for two enzyme replacement medicines for rare metabolic diseases known as Strensiq and Kanuma. Alexion acquired the latter product after buying Synageva earlier this year. Santhera Pharmaceuticals had announced that its Raxone drug had also won a positive recommendation for treating Leber's hereditary optic neuropathy. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.   (Reporting by Ben Hirschler, editing by William Hardy)",2015-06-26,ALXN,"Fri Jun 26, 2015 | 7:13am EDT","Europe gives green light to new Novartis, Alexion drugs",http://www.reuters.com//article/pharmaceuticals-europe-novartis-alexion-idUSL8N0ZC1X220150626?type=companyNews
20,"  July 2 Lonza Group AG :* Announces additional long-term agreement with Alexion * New manufacturing line to be constructed at Lonza's existing Portsmouth, NH (USA) plant  * Large-scale, manufacturing line will be operational by end of 2017  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",2015-07-02,ALXN,"Thu Jul 2, 2015 | 1:10am EDT",BRIEF-Lonza announces additional long-term agreement with Alexion,http://www.reuters.com//article/idUSFWN0ZH02420150702?type=companyNews
21,"   By Bill Berkrot | NEW YORK  NEW YORK Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.European health regulators approved Kanuma for patients with lysosomal acid lipase deficiency (LAL-D). They also approved Strensiq for patients with pediatric-onset hypophosphatasia (HPP), a drug Alexion had previously acquired. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration.""This is sort of a momentous year for us,"" Alexion Chief Executive David Hallal said in an interview. ""We're moving from a one-drug company to a three-drug company, eight, nine years after the launch of our first drug.""LAL-D is a progressive metabolic disease that often leads to liver failure, multi-organ damage and premature death. HPP is a progressive metabolic disease that can lead to deformity of bones, fractures and other skeletal abnormalities, as well as   muscle weakness, seizures, pain, and respiratory failure, causing death in infants and children.Both are ultra-rare diseases defined as occurring in fewer than 20 patients per one million in the general population.Hallal said he expects Kanuma to eventually generate more than $1 billion in annual sales. He declined to provide a sales forecast for Strensiq. He sees a slow sales uptake for the drugs as raising awareness of the diseases and identifying patients is one of the biggest challenges facing the company. ""It takes time to reach the patients and the physicians,"" Hallal said. ""When we launch, it's usually one patient at a time.""Hallal said Alexion aims for similar pricing for the new drugs in the United States and elsewhere. ""The U.S. should not have to underwrite the cost,"" he said.   The price Alexion paid for Synageva, which was more than twice its market value, drew criticism on Wall Street. But it transforms Alexion into a multi-product company with a larger developmental pipeline.Alexion said the Synageva deal will add to profits beginning in 2018.Alexion sells Soliris for two rare diseases at a cost of around $500,000 a year. It had sales of $2.23 billion in 2014. It is in late stage testing of Soliris for three other rare conditions, and expects early stage data on another enzyme replacement therapy this year.In addition, ""we added another 12 preclinical programs from Synageva to our pipeline,"" Hallal said.Alexion shares fell $1.32 to close at $170.87 on Nasdaq. (Reporting by Bill Berkrot and Caroline Humer; Editing by Andrew Hay and Frances Kerry)",2015-09-01,ALXN,"Tue Sep 1, 2015 | 4:06pm EDT",Alexion gets EU approval for drug acquired in Synageva deal,http://www.reuters.com//article/us-alexion-pharms-approval-idUSKCN0R14KO20150901?type=companyNews
22,"  (Adds further CEO comment, updates share price, paragraphs 9, 14, 15)By Bill BerkrotNEW YORK, Sept 1 Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.European health regulators approved Kanuma for patients with lysosomal acid lipase deficiency (LAL-D). They also approved Strensiq for patients with pediatric-onset hypophosphatasia (HPP), a drug Alexion had previously acquired. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration.""This is sort of a momentous year for us,"" Alexion Chief Executive David Hallal said in an interview. ""We're moving from a one-drug company to a three-drug company, eight, nine years after the launch of our first drug.""LAL-D is a progressive metabolic disease that often leads to liver failure, multi-organ damage and premature death. HPP is a progressive metabolic disease that can lead to deformity of bones, fractures and other skeletal abnormalities, as well as   muscle weakness, seizures, pain, and respiratory failure, causing death in infants and children. Both are ultra-rare diseases defined as occurring in fewer than 20 patients per one million in the general population.Hallal said he expects Kanuma to eventually generate more than $1 billion in annual sales. He declined to provide a sales forecast for Strensiq.He sees a slow sales uptake for the drugs as raising awareness of the diseases and identifying patients is one of the biggest challenges facing the company. ""It takes time to reach the patients and the physicians,"" Hallal said. ""When we launch, it's usually one patient at a time.""Hallal said Alexion aims for similar pricing for the new drugs in the United States and elsewhere. ""The U.S. should not have to underwrite the cost,"" he said.The price Alexion paid for Synageva, which was more than twice its market value, drew criticism on Wall Street. But it transforms Alexion into a multi-product company with a larger developmental pipeline. Alexion said the Synageva deal will add to profits beginning in 2018.Alexion sells Soliris for two rare diseases at a cost of around $500,000 a year. It had sales of $2.23 billion in 2014.It is in late stage testing of Soliris for three other rare conditions, and expects early stage data on another enzyme replacement therapy this year.In addition, ""we added another 12 preclinical programs from Synageva to our pipeline,"" Hallal said.Alexion shares fell $1.32 to close at $170.87 on Nasdaq.   (Reporting by Bill Berkrot and Caroline Humer; Editing by Andrew Hay and Frances Kerry)",2015-09-01,ALXN,"Tue Sep 1, 2015 | 4:03pm EDT",UPDATE 1-Alexion gets EU approval for drug acquired in Synageva deal,http://www.reuters.com//article/alexion-pharms-approval-idUSL1N1171YL20150901?type=companyNews
23,"  (Adds Alexion Pharmaceuticals, Saint-Gobain, Novo Banco and others)Sept 1 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:** Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc  announced on Tuesday European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.** BG Group plc, which is being acquired by Royal Dutch Shell plc, has put up for sale its 22.2 percent stake in the huge Thai Bongkot offshore gas field valued at around $1.2 billion, people familiar with the matter said.** A Swiss court confirmed that Saint-Gobain did not have to launch a mandatory public takeover bid for all the shares of Swiss chemical firm Sika, the French group said on Tuesday.** The Bank of Portugal has failed to reach an agreement with China's Anbang Insurance Group Co in exclusive talks over the sale of state-rescued Novo Banco and will now open talks with the second-placed bidder.** Canada's Westport Innovations Inc, which develops motor vehicle engines that run on natural gas, agreed to buy U.S. peer Fuel Systems Solutions Inc in an all-stock deal to diversify from engines for trucks and buses.** Online gambling firm 888 Holdings Plc stepped up the battle for Bwin.party Digital Entertainment Plc on Tuesday, submitting a revised takeover proposal as it looks to see off rival interest from GVC Holdings Plc.** Finland is planning to sell shares in state-owned companies worth about 1.6 billion euros ($1.80 billion) by 2018 to finance growth projects, a senior official said on Tuesday. ** Suitors are not lining up to buy Italian bank Monte dei Paschi di Siena, one of its core shareholders said on Tuesday, months having passed since a request by the European Central Bank for it to find a partner.** British caravan holiday park operator Park Resorts will merge with rival Parkdean Holidays in a deal which will create a combined business worth 960 million pounds ($1.5 billion), Park Resorts' owner Electra Private Equity said.** Arclin Inc, a maker of resins and other construction-related materials, has hired investment bank Credit Suisse Group AG to explore a sale that could value it at around $800 million, according to people familiar with the matter.** Japan's Ajinomoto Co Inc has about 150-200 billion yen ($1.3 billion-$1.7 billion) that it could spend on acquisitions and alliances by its 2016 fiscal year, its president said, as it aims to become a top-10 global food company in the coming years.** British support services company Rentokil Initial  has continued its North American expansion with its biggest deal in 10 years, agreeing to buy pest control business Steritech for $425 million. ** French oil major Total said it had agreed to sell some of its retail activities in Turkey to diversified conglomerate Demiroren for 325 million euros ($365 million).** Whirlpool Corp, the world's biggest home appliance company, is set to battle Middleby for Britain's Aga Rangemaster, the maker of range cookers synonymous with affluent British middle-class country life.** One Equity Partners, the former middle-market private equity arm of JPMorgan Chase & Co, is acquiring Augusta Columbia Capital, a buyout firm focused on technology investing, according to people familiar with the matter.** Copper miner Antofagasta Plc said it would merge its majority-owned unit, Minera Centinela, with its fully-owned subsidiary CCM Encuentro, which owns a sulphide project in northern Chile. ** Malaysia's finance ministry has taken up a substantial stake in defense services provider and contractor Destini Bhd , The Star reported on Tuesday, citing sources.** Russian state airline Aeroflot said on Tuesday it would acquire a 75-percent stake in struggling competitor Transaero, creating one of the world's largest air transport companies.** Baring Private Equity Asia said on Tuesday it acquired 40 percent of Weetabix Ltd, Britain's largest branded manufacturer of cereals and cereal bars, for an undisclosed sum, looking to benefit from rising consumer demand in China for healthy food products.** German home-improvement chain Obi plans to take over most of the sites of its struggling Austrian rival BauMax, Austria's competition authority, BWB, said on Tuesday, adding that Obi would take on the affected staff.** Private equity firm EQT has decided to sell Swedish education company Academedia, with a market listing a leading option, an EQT spokeswoman said.** Bild tabloid publisher Axel Springer and Korean electronics group Samsung announced a partnership in mobile media including news.** Trading house Gunvor, which has been selling assets in Russia, has again emerged as the winner of a semi-annual Rosneft  tender, traders said on Tuesday.** Sun International, South Africa's second-biggest hotel and gaming operator, has finalized a merger of its Latin American business with Chile's Dreams SA to create a group valued at about $400 million, it said on Tuesday.    ($1 = 0.89 euros)   (Compiled by Manish Parashar and Yashaswini Swamynathan in Bengaluru)",2015-09-01,ALXN,"Tue Sep 1, 2015 | 4:01pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N1173I020150901?type=companyNews
24,"  (Corrects headline and paragraphs 1, 2 to show only one of the two drugs approved by European regulators was acquired in the Synageva deal)By Bill BerkrotNEW YORK, Sept 1 Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.European health regulators approved Kanuma for patients with lysosomal acid lipase deficiency (LAL-D). They also approved Strensiq for patients with pediatric-onset hypophosphatasia (HPP), a drug that Alexion had previously acquired. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration.""This is sort of a momentous year for us,"" Alexion Chief Executive David Hallal said in an interview. ""We're moving from a one-drug company to a three-drug company, eight, nine years after the launch of our first drug.""LAL-D is a progressive metabolic disease that often leads to liver failure, multi-organ damage and premature death. HPP is a progressive metabolic disease that can lead to deformity of bones, fractures and other skeletal abnormalities, as well as  profound muscle weakness, seizures, pain, and respiratory failure, causing death in infants and children. Both are ultra-rare diseases defined as occurring in fewer than 20 patients per one million in the general population.Hallal said he expects Kanuma to eventually generate more than $1 billion in annual sales. He declined to provide a sales forecast for Strensiq.He sees a slow sales uptake for the drugs as raising awareness of the diseases and identifying patients is one of the biggest challenges facing the company. ""It takes time to reach the patients and the physicians,"" Hallal said. ""When we launch, it's usually one patient at a time.""The price Alexion paid for Synageva, which was more than twice its market value, raised eyebrows and drew criticism on Wall Street. But it transforms Alexion into a multi-product company with a much larger developmental pipeline. Alexion said the Synageva deal will add to profits beginning in 2018.Alexion currently sells Soliris for two extremely rare diseases at a cost of around $500,000 a year. It had sales of $2.23 billion in 2014.It is in late stage testing of Soliris for three other rare conditions, and expects early stage data on another enzyme replacement therapy later this year.On top of that, ""we added another 12 preclinical programs from Synageva to our pipeline,"" Hallal said.""In aggregate we felt really good with the premium(we paid for Synageva),"" he said. ""We have an opportunity now to accelerate and diversify our revenue.""    (Reporting by Bill Berkrot and Caroline Humer; Editing by Andrew Hay and Frances Kerry)",2015-09-01,ALXN,"Tue Sep 1, 2015 | 3:29pm EDT",CORRECTED-Alexion gets EU approval for drug acquired in Synageva deal,http://www.reuters.com//article/alexion-pharms-approval-idUSL1N1171R620150901?type=companyNews
25,"  Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp.European health regulators on Tuesday approved the drug, Kanuma, to treat lysosomal acid lipase deficiency (LAL-D), a progressive metabolic disease that often leads to liver failure, multi-organ damage and premature death.The FDA, which has granted the drug ""breakthrough therapy"" status for LAL deficiency in infants, was expected to make its decision by Sept. 8.Alexion said on Friday it had submitted some additional ""chemistry, manufacturing and controls"" information that the FDA asked for, and that the timing of the submission had caused the delay.The regulator has not asked for any addition clinical data on the enzyme-replacement therapy for the ultra-rare, life threatening disease, the company said. An application to market Kanuma in Japan has also been submitted.Kanuma could eventually bring in than $1 billion in annual sales, Alexion Chief Executive David Hallal told Reuters earlier this week. On Tuesday, European health regulators also approved Alexion's Strensiq to treat pediatric-onset hypophosphatasia (HPP), a potentially fatal disease that can lead to bone deformity, fractures and other skeletal abnormalities.Prior to these approvals, Alexion's sole approved drug was Soliris, which treats two rare and life-threatening diseases: Paroxysmal nocturnal hemoglobinuria, and Atypical hemolytic uremic syndrome. It raked in sales of $2.23 billion last year. Alexion's shares closed at $175.28 on Thursday. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-09-04,ALXN,"Fri Sep 4, 2015 | 8:54am EDT",FDA delays decision on key Alexion drug by 3 months,http://www.reuters.com//article/us-alexion-pharms-fda-idUSKCN0R41GD20150904?type=companyNews
26,"  Sept 4 Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp.European health regulators on Tuesday approved the drug, Kanuma, to treat lysosomal acid lipase deficiency (LAL-D), a progressive metabolic disease that often leads to liver failure, multi-organ damage and premature death.The FDA, which has granted the drug ""breakthrough therapy"" status for LAL deficiency in infants, was expected to make its decision by Sept. 8.Alexion said on Friday it had submitted some additional ""chemistry, manufacturing and controls"" information that the FDA asked for, and that the timing of the submission had caused the delay. The regulator has not asked for any addition clinical data on the enzyme-replacement therapy for the ultra-rare, life threatening disease, the company said.An application to market Kanuma in Japan has also been submitted. Kanuma could eventually bring in than $1 billion in annual sales, Alexion Chief Executive David Hallal told Reuters earlier this week. On Tuesday, European health regulators also approved Alexion's Strensiq to treat pediatric-onset hypophosphatasia (HPP), a potentially fatal disease that can lead to bone deformity, fractures and other skeletal abnormalities.Prior to these approvals, Alexion's sole approved drug was Soliris, which treats two rare and life-threatening diseases: Paroxysmal nocturnal hemoglobinuria, and Atypical hemolytic uremic syndrome. It raked in sales of $2.23 billion last year.Alexion's shares closed at $175.28 on Thursday.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-09-04,ALXN,"Fri Sep 4, 2015 | 8:49am EDT",FDA delays decision on key Alexion drug by 3 months,http://www.reuters.com//article/alexion-pharms-fda-idUSL4N11A2TC20150904?type=companyNews
27,"  (Adds details, share movement)Oct 23 The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's Strensiq, a treatment for a rare kind of metabolic bone disorder.The approval is the first in the United States for a treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP). (1.usa.gov/1W9KuRH) HPP is a genetic and potentially fatal disorder that weakens bones, leading to skeletal abnormalities, with the most severe forms tending to occur before birth and in early infancy.The debilitating disorder affects fewer than 200,000 patients in the United States, the FDA said. Strensiq, to be administered by injection three or six times a week, was approved by Japan health regulators in July. Alexion said it expects the drug to be commercially available in the United States on Oct. 27.Alexion's shares were up about 2.7 percent at $175.70 in after-market trade. The Cheshire, Connecticut-based company's shares closed at $171.16 on the Nasdaq on Friday.   (Reporting by Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)",2015-10-23,ALXN,"Fri Oct 23, 2015 | 4:38pm EDT",UPDATE 1-FDA approves Alexion's metabolic bone disorder drug,http://www.reuters.com//article/alexion-pharms-fda-idUSL3N12N59S20151023?type=companyNews
28,"  The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's Strensiq, a treatment for a rare kind of metabolic disorder.Strensiq is designed to treat perinatal, infantile and juvenile-onset hypophosphatasia, a genetic and potentially fatal disorder that affects multiple systems of the body, which could lead to severe complications. (1.usa.gov/1W9KuRH)    (Reporting by Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)",2015-10-23,ALXN,"Fri Oct 23, 2015 | 4:04pm EDT",FDA approves Alexion Pharma's metabolic disorder drug,http://www.reuters.com//article/us-alexion-pharms-fda-idUSKCN0SH2GB20151023?type=companyNews
29,"  LONDON A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more than $550,000 a year for each patient has been deemed too expensive by Britain's health cost watchdog NICE.The case highlights the sky-high price of some medicines for treating rare diseases and the dilemma this poses for cash-strapped healthcare providers.The National Institute for Health and Care Excellence (NICE) does not dispute that Alexion's Strensiq is effective for the handful of patients, estimated at around seven a year in England, diagnosed with pediatric-onset hypophosphatasia. But NICE said on Wednesday it was not satisfied that Alexion had provided an adequate justification for the drug's high price of 366,912 pounds ($552,000) per patient a year, assuming an average weight of 19.3 kg.Left untreated, hypophosphatasia causes weakening of bones and can lead to chronic debilitating pain, muscle weakness, generalized seizures because of vitamin B6 deficiency, as well as renal and respiratory complications. The NICE decision is still at the draft stage and is open to a period of consultation.   (Reporting by Ben Hirschler; editing by David Clarke)",2015-12-03,ALXN,"Wed Dec 2, 2015 | 7:44pm EST","Alexion's $550,000 bone drug too expensive for Britain",http://www.reuters.com//article/us-alexion-pharms-britain-idUSKBN0TM02420151203?type=companyNews
30,"  LONDON Dec 3 A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals  that costs more than $550,000 a year for each patient has been deemed too expensive by Britain's health cost watchdog NICE.The case highlights the sky-high price of some medicines for treating rare diseases and the dilemma this poses for cash-strapped healthcare providers.The National Institute for Health and Care Excellence (NICE) does not dispute that Alexion's Strensiq is effective for the handful of patients, estimated at around seven a year in England, diagnosed with paediatric-onset hypophosphatasia. But NICE said on Wednesday it was not satisfied that Alexion had provided an adequate justification for the drug's high price of 366,912 pounds ($552,000) per patient a year, assuming an average weight of 19.3 kg. Left untreated, hypophosphatasia causes weakening of bones and can lead to chronic debilitating pain, muscle weakness, generalised seizures because of vitamin B6 deficiency, as well as renal and respiratory complications. The NICE decision is still at the draft stage and is open to a period of consultation.  ($1 = 0.6650 pounds)   (Reporting by Ben Hirschler; editing by David Clarke)",2015-12-03,ALXN,"Wed Dec 2, 2015 | 7:00pm EST","Alexion's $550,000 bone drug too expensive for Britain",http://www.reuters.com//article/alexion-pharms-britain-idUSL8N13R1YF20151203?type=companyNews
31,"   By Bill Berkrot and Samantha Kareen Nair  The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc's treatment for an ultra-rare and potentially fatal genetic disorder.Alexion's enzyme-replacement therapy, Kanuma, which received European approval in September, was approved to treat patients, including infants, with lysosomal acid lipase deficiency (LAL-D), that can lead to liver failure, heart disease and early death.Alexion shares were up $8.07, or 4.5 percent, at $187.22. There are only a few thousand patients with LAL-D in the United States, Alexion said. It estimates four to eight babies per year will be born with the infantile form of LAL-D. But life-saving treatments for ultra-rare diseases can command extremely high prices.The company believes Kanuma will eventually generate annual sales in excess of $1 billion.""But given the extremely low awareness of this disease, the high mortality and low incidence in prevalence, we would expect the dynamics of this launch to be slow and steady,"" Alexion Chief Executive David Hallal said in a telephone interview. ""It takes many years in ultra-rare diseases to reach a $1 billion threshold."" Onset of LAL-D tends to happen around the age of 5. Infants born with the disease usually die before their first birthday.In a clinical trial, six of nine babies who received Kanuma  survived beyond 12 months.""We expect that over time we'll have success in identifying patients with the disease and help them get the treatment,"" Hallal said. Kanuma, which the company acquired with its $8.4 billion purchase of Synageva BioPharma in June, could be priced at $300,000 to $400,000 annually, Morningstar analyst Stefan Quenneville forecast.Alexion's flagship drug Soliris, which treats two rare diseases and is in late-stage testing for three more, costs around $500,000 a year. The company plans to discuss pricing for Kanuma later on Tuesday. Unlike most drugmakers that charge much higher prices for medicines sold in the United States, Alexion plans similar pricing globally. ""That's a strong belief that we have that our drug launches outside of the U.S. should not be subsidized by the U.S.,"" Hallal said.  Kanuma is developed from the egg whites of genetically engineered chickens and required approval from both the FDA's veterinary division and its normal drug evaluation division.""Using this technology, these patients for the first time ever have access to a treatment that may improve their lives and chances of survival,"" FDA drug evaluation director Janet Woodcock said in a statement. (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian and James Dalgleish)",2015-12-08,ALXN,"Tue Dec 8, 2015 | 1:16pm EST",FDA approves Alexion drug for ultra-rare disease,http://www.reuters.com//article/us-alexion-pharms-fda-idUSKBN0TR1YQ20151208?type=companyNews
32,"  (Adds CEO interview, FDA comment, updates shares)By Bill Berkrot and Samantha Kareen NairDec 8 The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc's treatment for an ultra-rare and potentially fatal genetic disorder.Alexion's enzyme-replacement therapy, Kanuma, which received European approval in September, was approved to treat patients, including infants, with lysosomal acid lipase deficiency (LAL-D), that can lead to liver failure, heart disease and early death.Alexion shares were up $8.07, or 4.5 percent, at $187.22.There are only a few thousand patients with LAL-D in the United States, Alexion said. It estimates four to eight babies per year will be born with the infantile form of LAL-D. But life-saving treatments for ultra-rare diseases can command extremely high prices. The company believes Kanuma will eventually generate annual sales in excess of $1 billion.""But given the extremely low awareness of this disease, the high mortality and low incidence in prevalence, we would expect the dynamics of this launch to be slow and steady,"" Alexion Chief Executive David Hallal said in a telephone interview. ""It takes many years in ultra-rare diseases to reach a $1 billion threshold.""Onset of LAL-D tends to happen around the age of 5. Infants born with the disease usually die before their first birthday. In a clinical trial, six of nine babies who received Kanuma  survived beyond 12 months.""We expect that over time we'll have success in identifying patients with the disease and help them get the treatment,"" Hallal said.Kanuma, which the company acquired with its $8.4 billion purchase of Synageva BioPharma in June, could be priced at $300,000 to $400,000 annually, Morningstar analyst Stefan Quenneville forecast. Alexion's flagship drug Soliris, which treats two rare diseases and is in late-stage testing for three more, costs around $500,000 a year.The company plans to discuss pricing for Kanuma later on Tuesday. Unlike most drugmakers that charge much higher prices for medicines sold in the United States, Alexion plans similar pricing globally.""That's a strong belief that we have that our drug launches outside of the U.S. should not be subsidized by the U.S.,"" Hallal said.Kanuma is developed from the egg whites of genetically engineered chickens and required approval from both the FDA's veterinary division and its normal drug evaluation division.""Using this technology, these patients for the first time ever have access to a treatment that may improve their lives and chances of survival,"" FDA drug evaluation director Janet Woodcock said in a statement.   (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian and James Dalgleish)",2015-12-08,ALXN,"Tue Dec 8, 2015 | 1:11pm EST",UPDATE 2-FDA approves Alexion drug for ultra-rare disease,http://www.reuters.com//article/alexion-pharms-fda-idUSL3N13X4VM20151208?type=companyNews
33,"  Dec 8 The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc's treatment for a rare and potentially fatal genetic disorder.Alexion's enzyme-replacement therapy, Kanuma, aims to treat patients with lysosomal acid lipase deficiency (LAL-D), a type of genetic disorder that often leads to multi-organ damage and premature death. (1.usa.gov/1QcP3qN)  Kanuma was added to the drugmaker's pipeline through its acquisition of Synageva BioPharma Corp in a deal worth $8.4 billion that closed in June.   (Reporting by Rosmi Shaji and Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza) ",2015-12-08,ALXN,"Tue Dec 8, 2015 | 10:57am EST",FDA approves Alexion Pharma's enzyme-replacement therapy,http://www.reuters.com//article/alexion-pharms-fda-idUSL3N13K4MB20151208?type=companyNews
34,"  LONDON An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.Kanuma is designed for treating lysosomal acid lipase (LAL) deficiency, a rare inherited genetic disease in which fats build up in cells. Rapidly progressing LAL deficiency is particularly serious in babies, with survival of less than 12 months.The National Institute for Health and Care Excellence (NICE), which decides if drugs should be used on the state health service, said in draft guidance on Thursday that more research was needed on the drug's costs and benefits. Alexion said NICE had failed to recognize the ""transformative clinical innovation of Kanuma"", adding the drug had shown major survival benefit in babies and significant improvements in children and adults with LAL deficiency. ($1 = 0.6982 pounds)  (Reporting by Ben Hirschler; Editing by David Holmes)",2016-02-18,ALXN,"Thu Feb 18, 2016 | 3:30am EST","UK cost agency queries value of $700,000-a-year Alexion drug",http://www.reuters.com//article/us-britain-alexion-idUSKCN0VR003?type=companyNews
35,"  LONDON An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.Kanuma is designed for treating lysosomal acid lipase (LAL) deficiency, a rare inherited genetic disease in which fats build up in cells. Rapidly progressing LAL deficiency is particularly serious in babies, with survival of less than 12 months.The National Institute for Health and Care Excellence (NICE), which decides if drugs should be used on the state health service, said in draft guidance on Thursday that more research was needed on the drug's costs and benefits. Alexion said NICE had failed to recognize the ""transformative clinical innovation of Kanuma"", adding the drug had shown major survival benefit in babies and significant improvements in children and adults with LAL deficiency. ($1 = 0.6982 pounds)  (Reporting by Ben Hirschler; Editing by David Holmes)",2016-02-18,ALXN,"Thu Feb 18, 2016 | 3:30am EST","UPDATE 1-UK cost agency queries value of $700,000-a-year Alexion drug",http://www.reuters.com//article/britain-alexion-idUSL8N15X1MY?type=companyNews
36,"  LONDON Feb 18 An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.Kanuma is designed for treating lysosomal acid lipase (LAL) deficiency, a rare inherited genetic disease in which fats build up in cells. Rapidly progressing LAL deficiency is particularly serious in babies, with survival of less than 12 months. The National Institute for Health and Care Excellence (NICE), which decides if drugs should be used on the state health service, said in draft guidance on Thursday that more research was needed on the drug's costs and benefits.  ($1 = 0.6982 pounds)   (Reporting by Ben Hirschler; Editing by David Holmes)",2016-02-18,ALXN,"Wed Feb 17, 2016 | 7:01pm EST","UK cost agency queries value of $700,000-a-year Alexion drug",http://www.reuters.com//article/britain-alexion-idUSL8N15W4LV?type=companyNews
37,  March 28 Alexion Pharmaceuticals Inc * Kanuma receives marketing approval in japan for treatment of patients with lysosomal acid lipase deficiency  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ,2016-03-28,ALXN,"Mon Mar 28, 2016 | 6:49am EDT",BRIEF-Alexion Pharmaceuticals Kanuma receives marketing approval in Japan,http://www.reuters.com//article/idUSFWN16W0R3?type=companyNews
38,  March 31 Alexion Pharmaceuticals Inc* Says CFO Vikas Sinha FY 2015 total compensation $4.7 million versus $7 million in FY 2014 - sec filing * Former CEO Leonard Bell 2015 total compensation of $24.9 million versus $20.6 million in 2014- sec filing  * CEO David Hallal 2015 total compensation of $14.7 million versus $7.5 million in 2014- sec filing    Source text for Eikon:    Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780),2016-03-31,ALXN,"Thu Mar 31, 2016 | 5:43pm EDT",BRIEF-Alexion says CEO David Hallal's 2015 compensation was $14.7 mln,http://www.reuters.com//article/idUSFWN1730VL?type=companyNews
39,"  Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.Shares were trading down 11 percent at $138.71 in extended trade.The drug is being studied as a potential treatment for refractory generalized myasthenia gravis, a debilitating neuromuscular disease.In myasthenia gravis, patients who have largely exhausted conventional therapy, continue to suffer profound muscle weakness, resulting in slurred speech, impaired swallowing and choking, and episodes of respiratory failure. In the study, the primary efficacy endpoint of change from baseline at week 26 did not reach statistical significance.Soliris is already approved for the rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris had sales of $2.59 billion in 2015.The company said it continues to analyze the study data and expects to give detailed results from the trial in early July. Shares of Alexion closed $154.99 on Monday on Nasdaq. (Reporting by Shailesh Kuber in Bengaluru; Editing by Shounak Dasgupta)",2016-06-06,ALXN,"Mon Jun 6, 2016 | 5:47pm EDT",Alexion shares slump as drug misses goal in late-stage trial,http://www.reuters.com//article/us-alexion-pharms-study-idUSKCN0YS2BQ?type=companyNews
40,"  Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.Shares were trading down 11 percent at $138.71 in extended trade.The drug is being studied as a potential treatment for refractory generalized myasthenia gravis, a debilitating neuromuscular disease.In myasthenia gravis, patients who have largely exhausted conventional therapy, continue to suffer profound muscle weakness, resulting in slurred speech, impaired swallowing and choking, and episodes of respiratory failure. In the study, the primary efficacy endpoint of change from baseline at week 26 did not reach statistical significance.Soliris is already approved for the rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris had sales of $2.59 billion in 2015.The company said it continues to analyze the study data and expects to give detailed results from the trial in early July. Shares of Alexion closed $154.99 on Monday on Nasdaq. (Reporting by Shailesh Kuber in Bengaluru; Editing by Shounak Dasgupta)",2016-06-06,ALXN,"Mon Jun 6, 2016 | 5:47pm EDT",UPDATE 1-Alexion shares slump as drug misses goal in late-stage trial,http://www.reuters.com//article/alexion-pharms-study-idUSL4N18Y47Z?type=companyNews
41,"  June 6 Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial, sending its shares down 9 percent in extended trade.The drug is being studied as a potential treatment for refractory generalized myasthenia gravis, a debilitating neuromuscular disease. Soliris is already approved for the rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.  Shares of Alexion closed $154.99 on Monday on Nasdaq.   (Reporting by Shailesh Kuber; Editing by Shounak Dasgupta)",2016-06-06,ALXN,"Mon Jun 6, 2016 | 4:49pm EDT",Alexion drug misses goal in late-stage trial,http://www.reuters.com//article/alexion-pharms-study-idUSL4N18Y47D?type=companyNews
42,  June 6 Alexion Pharmaceuticals Inc* Alexion announces topline results from Phase 3 regain study of eculizumab (soliris) in patients with refractory generalized myasthenia gravis (GMG) * Primary endpoint of regain study missed statistical significance * Alexion continues to analyze data from regain study * Four patients receiving eculizumab (6.5 pct) discontinued treatment due to an adverse event  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780),2016-06-06,ALXN,"Mon Jun 6, 2016 | 4:09pm EDT",BRIEF-Alexion announces topline results from Phase 3 regain study of eculizumab,http://www.reuters.com//article/idUSFWN18Y0J7?type=companyNews
43,"  * S&P 500 nears 2015 record high* Oil prices hit 2016 highs* Biogen, Alexion drop after drug trial failures* Dow up 0.3 pct, S&P up 0.3 pct, Nasdaq down 0.04 pct   (Updates to late afternoon)By Caroline ValetkevitchJune 7 The S&P 500 rose to within 15 points of its record high on Tuesday, helped by a big jump in energy shares and enthusiasm following Federal Reserve Chair Janet Yellen's speech this week.Volume was relatively light, though, and the Nasdaq was slightly lower. Biotech shares dropped following disappointing news from several key companies including Biogen. The Nasdaq Biotech Index was down 2.2 percent. Giving the S&P 500 its biggest boost, the S&P energy index  jumped 2.3 percent and was on track for its best two-day percentage gain since March. Oil prices reached 2016 highs due to supply constraints and a weak dollar.Gains this week have once again put the S&P 500 within striking distance of record highs reached in May 2015. Comments from Yellen on Monday seemed to ease some worries about the economy while underscoring views the Fed may be in no rush to raise rates.""The big story for the market right now is, do we break out to all-time highs,"" said Michael Sheldon, chief investment officer at Northstar Wealth Partners in West Hartford, Connecticut. ""If we do so in the near term, we could see a rush of money jump into the market from investors who had been sitting out on the sidelines, in fear missing out on further market gains."" At 3:18 p.m., the Dow Jones industrial average was up 48.39 points, or 0.27 percent, to 17,968.72, the S&P 500  gained 5.74 points, or 0.27 percent, to 2,115.15 and the Nasdaq Composite dropped 2.12 points, or 0.04 percent, to 4,966.59.The Dow earlier in the day traded above 18,000, while the S&P hit its highest level since late July.On the downside, the healthcare index dropped 0.5 percent, dragged down by Biogen and Alexion. Biogen tumbled 12.3 percent to $254.08, and was the biggest drag on the Nasdaq and the S&P 500, after its multiple sclerosis drug failed in a mid-stage study.Alexion dropped 10.7 percent to $138.18 after its drug failed a trial, while Valeant slumped 13 percent to $25.12 after the drugmaker cut its full-year forecast.One of the few bright spots among biotechs was Sarepta , which surged 25 percent on hopes that its muscle-wasting treatment could yet win U.S. approval.Advancing issues outnumbered declining ones on the NYSE by 1,930 to 1,085, for a 1.78-to-1 ratio on the upside; on the Nasdaq, 1,532 issues rose and 1,286 fell for a 1.19-to-1 ratio favoring advancers.The S&P 500 posted 43 new 52-week highs and 1 new low; the Nasdaq recorded 80 new highs and 19 new lows.      (additional reporting by Yashaswini Swamynathan in Bengaluru; Editing by Savio D'Souza)",2016-06-07,ALXN,"Tue Jun 7, 2016 | 3:39pm EDT",US STOCKS-S&P edges closer to record high; energy shares lead,http://www.reuters.com//article/usa-stocks-idUSL1N18Z1XN?type=companyNews
44,"  June 10 Alexion Pharmaceuticals Inc :* Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210* Once-Monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase * Says no serious adverse events or study withdrawals were observed in either patient cohort* 2 patients experienced serious treatment-related adverse events and one patient had a grade 2 infusion-related reaction * Says six deaths were reported, none of which were considered related to treatment with ALXN1007 * Says were no grade 3 or higher non-serious adverse events related to treatment with ALXN1007* Says one patient withdrew from study due to a treatment-emergent adverse event    Source text for Eikon:  Further company coverage:     (Bengaluru Newsroom)",2016-06-10,ALXN,"Fri Jun 10, 2016 | 3:01am EDT",BRIEF-Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210,http://www.reuters.com//article/idUSASC08TKF?type=companyNews
45,  July 14 Alexion Pharmaceuticals :* Alexion presents new SBC-103 (Rhnaglu enzyme) phase 1/2 data on brain MRI and neurocognitive assessments in patients with mucopolysaccharidosis iiib (MPS IIIB)  * Preliminary evidence suggest potential for dose-dependent disease stabilization in patients treated with SBC-103 at 6 months  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-07-14,ALXN,"Thu Jul 14, 2016 | 9:25am EDT",BRIEF-Alexion presents new SBC-103 data in patients with MPS iiiB,http://www.reuters.com//article/idUSASC08WY1?type=companyNews
46,"  July 28 Alexion Pharmaceuticals Inc :* Sees FY non gaap  earnings per share $4.50 to $4.65* Sees FY non gaap total revenues $3,050 to $3,100 million* FY2016 earnings per share view $5.05, revenue view $3.06 billion -- Thomson Reuters I/B/E/S * Alexion reports second quarter 2016 results* Q2 non-gaap earnings per share $1.13 * Q2 gaap earnings per share $0.51* Q2 revenue $753 million versus I/B/E/S view $742.7 million * Q2 earnings per share view $1.17 -- Thomson Reuters I/B/E/S* Sees FY gaap earnings per share $1.91 to $2.26* Sees FY gaap total revenues $3,050 to $3,100 million  Source text for Eikon:  Further company coverage:",2016-07-28,ALXN,"Thu Jul 28, 2016 | 6:48am EDT",BRIEF-Alexion reports Q2 non-gaap EPS $1.13,http://www.reuters.com//article/idUSASC08YZW?type=companyNews
47,"  Aug 8 Alexion Pharmaceuticals Inc* Fda recently completed  routine current good manufacturing practice inspection of Co's Smithfield, Rhode island manufacturing facility* FDA observations also pertain to monitoring of water systems * Based on current information, alexion anticipates that supply of soliris to patients will not be interrupted * FDA observations pertain to completion, closure of certain investigations, validation of surface sampling methods * Based on current information, does not anticipate material financial impact to resolve outstanding fda concerns  Source text for Eikon:  Further company coverage:",2016-08-08,ALXN,"Mon Aug 8, 2016 | 5:20pm EDT","BRIEF-Alexion Pharmaceuticals-FDA recently completed  routine current good manufacturing practice inspection of Co's Smithfield, Rhode Island Manufacturing Facility",http://www.reuters.com//article/idUSFWN1AP0VV?type=companyNews
48,  Aug 29 Alexion Pharmaceuticals Inc* European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD)  * ALXN1007 is currently being evaluated in a phase 2 study in patients with newly diagnosed acute GI-GVHD  Source text for Eikon:  Further company coverage: ,2016-08-29,ALXN,"Mon Aug 29, 2016 | 5:00pm EDT",BRIEF-Alexion gets orphan drug designation for ALXN1007,http://www.reuters.com//article/idUSFWN1BA0D2?type=companyNews
49,"  Oct 27 Alexion Pharmaceuticals Inc* Alexion reports third quarter 2016 results* Q3 non-gaap earnings per share $1.23* Q3 gaap earnings per share $0.42 * Q3 revenue $799 million versus I/B/E/S view $786.9 million * Sees fy 2016 gaap earnings per share $1.79 to $2.09* Q3 earnings per share view $1.17 -- Thomson Reuters I/B/E/S * Alexion Pharmaceuticals Inc says expects 2016 total revenues to be at upper end of previously guided range of $3.05 to $3.10 billion* Fy2016 earnings per share view $4.67, revenue view $3.08 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bangalore.newsroom@thomsonreuters.com)",2016-10-27,ALXN,"Thu Oct 27, 2016 | 6:45am EDT",BRIEF-Alexion Pharmaceuticals posts Q3 non-gaap EPS of $1.23,http://www.reuters.com//article/idUSASC09DKS?type=companyNews
50,  Oct 27 Alexion Pharmaceuticals Inc* Alexion initiates simultaneous registration trials of ALXN1210 for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (ahus) * Trials to evaluate alxn1210 administered every eight weeks in patients with PNH and AHUS; enrollment to begin in q4 * Plans to initiate a Phase 3 trial of ALXN1210 in pediatric patients with ahus in 2017 * Commenced dosing of a new formulation of alxn1210 administered subcutaneously in healthy volunteers in a phase i study  Source text for Eikon:  Further company coverage:,2016-10-27,ALXN,"Thu Oct 27, 2016 | 6:43am EDT",BRIEF-Alexion initiates simultaneous registration trials of ALXN1210 for patients with PNH and AHUS,http://www.reuters.com//article/idUSFWN1CX0US?type=companyNews
51,  Nov 9 Alexion Pharmaceuticals Inc : * Files for non-timely 10-Q  Source text for Eikon: [ID:bit.ly/2fTifZm] Further company coverage:  ,2016-11-09,ALXN,"Wed Nov 9, 2016 | 6:13pm EST",BRIEF-Alexion Pharmaceuticals files for non-timely 10-Q,http://www.reuters.com//article/idUSFWN1DA167?type=companyNews
52,"  (Adds details, share price)Nov 10 Alexion Pharmaceuticals Inc said on Wednesday it was  investigating allegations made by a former employee regarding sales practices involving its flagship and costly blood disorder drug Soliris.Alexion said it delayed a quarterly report filing while the audit and finance committee of its board of directors investigates whether any of its personnel ""engaged in sales practices that were inconsistent with company policies and procedures.""Soliris, approved for the rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, had sales of $2.59 billion in 2015. The current U.S. list price for the specialty medication is about $480,000 per year. Alexion said the investigation had not so far uncovered anything that might require it to update previously reported results.The New Haven, Connecticut-based company also said it had retained an external adviser to assist it in the investigation. Shares of Alexion, which rose 6.5 percent on the Nasdaq on Wednesday, were down 2.3 percent at $124.25 in after-hours trading.(Reporting by Laharee Chatterjee and Deena Beasley; Editing by Anil D'Silva and Tom Brown)",2016-11-09,ALXN,"Wed Nov 9, 2016 | 6:09pm EST",UPDATE 1-Alexion says investigating Soliris sales practices,http://www.reuters.com//article/alexion-pharms-investigation-idUSL4N1DA6UE?type=companyNews
53,  Alexion Pharmaceuticals Inc said on Wednesday it was conducting an investigation into allegations made by a former employee regarding sales practices of blood disorder drug Soliris.The company said it had retained an external adviser to assist it in the investigation.    (Reporting by Laharee Chatterjee; Editing by Anil D'Silva),2016-11-09,ALXN,"Wed Nov 9, 2016 | 4:58pm EST",Alexion says investigating Soliris sales practices,http://www.reuters.com//article/us-alexion-pharms-investigation-idUSKBN1343LY?type=companyNews
54,  Alexion Pharmaceuticals Inc said on Wednesday it was conducting an investigation into allegations made by a former employee regarding sales practices of blood disorder drug Soliris.The company said it had retained an external adviser to assist it in the investigation.    (Reporting by Laharee Chatterjee; Editing by Anil D'Silva),2016-11-09,ALXN,"Wed Nov 9, 2016 | 4:58pm EST",Alexion says investigating Soliris sales practices,http://www.reuters.com//article/alexion-pharms-investigation-idUSL4N1DA6T7?type=companyNews
55,"  Nov 11 Alexion Pharmaceuticals Inc* Alexion says new long-term data show reduction in liver fibrosis and cirrhosis in cohort of patients with lysosomal acid lipase deficiency treated with Kanuma * Alexion Pharma says additional long-term data show rapid, sustained reduction in alt, in 98 percent of Kanuma-treated patients at 76 weeks  * Alexion Pharma says safety profile of Kanuma during extended open-label period was consistent with that observed in double-blind period  Source text for Eikon:  Further company coverage:",2016-11-11,ALXN,"Fri Nov 11, 2016 | 8:23am EST",BRIEF-Alexion says new long-term data show reduction in liver fibrosis and cirrhosis in cohort of patients with lysosomal acid lipase deficiency treated with Kanuma,http://www.reuters.com//article/idUSFWN1DC13A?type=companyNews
56,"  Nov 14 Paulson & Co* Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227,700 shares* Paulson & Co ups share stake in Fedex Corp by 47 percent to 106,800 shares * Paulson & Co takes 74,000 share stake in Alder Biopharmaceuticals Inc * Paulson & Co takes share stake of 628,100 shares in eBay Inc * Paulson & Co cuts share stake in Johnson & Johnson by 72.7 percent to 35,000 shares* Paulson & Co - change in holdings are as of September 30, 2016 and compared with the previous quarter ended as of June 30, 2016  Source text for quarter ended Sept 30, 2016:  (bit.ly/2fTvUfH) Source text for quarter ended June 30, 2016: (bit.ly/2aX5bxr)",2016-11-14,ALXN,"Mon Nov 14, 2016 | 5:38pm EST","BRIEF-Paulson & Co cuts share stake in Alexion Pharmaceuticals, Johnson & Johnson",http://www.reuters.com//article/idUSFWN1DF1JG?type=companyNews
57,  Nov 17 Alexion Pharmaceuticals Inc :* Alexion Pharmaceuticals Inc - new data from an analysis of patients enrolled in global atypical hemolytic uremic syndrome (aHUS) registry * Alexion Pharmaceuticals - results of data show starting soliris before transplant reduced likelihood of dialysis three-fold compared to post-transplant  * Results of data show need for dialysis increased after kidney transplant if soliris was discontinued  Source text for Eikon:  Further company coverage:,2016-11-17,ALXN,"Thu Nov 17, 2016 | 5:44pm EST",BRIEF-Alexion Pharmaceuticals announces new data,http://www.reuters.com//article/idUSFWN1DI0TC?type=companyNews
